Tasigna is a Oral Capsule in the Human Prescription Drug category. It is labeled and distributed by Novartis Pharmaceuticals Corporation. The primary component is Nilotinib.
Product ID | 0078-0526_404b85a1-6329-432c-a18f-a9588c009551 |
NDC | 0078-0526 |
Product Type | Human Prescription Drug |
Proprietary Name | Tasigna |
Generic Name | Nilotinib |
Dosage Form | Capsule |
Route of Administration | ORAL |
Marketing Start Date | 2007-10-29 |
Marketing Category | NDA / NDA |
Application Number | NDA022068 |
Labeler Name | Novartis Pharmaceuticals Corporation |
Substance Name | NILOTINIB |
Active Ingredient Strength | 200 mg/1 |
Pharm Classes | Kinase Inhibitor [EPC],Protein Kinase Inhibitors [MoA] |
NDC Exclude Flag | N |
Listing Certified Through | 2021-12-31 |
Marketing Start Date | 2007-10-29 |
NDC Exclude Flag | N |
Sample Package? | N |
Marketing Category | NDA |
Application Number | NDA022068 |
Product Type | HUMAN PRESCRIPTION DRUG |
Billing Unit | EA |
Marketing Start Date | 2007-10-29 |
Marketing Category | NDA |
Application Number | NDA022068 |
Product Type | HUMAN PRESCRIPTION DRUG |
Billing Unit | EA |
Marketing Start Date | 2007-10-29 |
Ingredient | Strength |
---|---|
NILOTINIB | 200 mg/1 |
SPL SET ID: | 6093952a-5248-45cb-ad17-33716a411146 |
Manufacturer | |
UNII | |
RxNorm Concept Unique ID - RxCUI | |
UPC Code |
NDC | Brand Name | Generic Name |
---|---|---|
0078-0526 | Tasigna | nilotinib |
0078-0592 | Tasigna | nilotinib |
0078-0951 | Tasigna | nilotinib |
Mark Image Registration | Serial | Company Trademark Application Date |
---|---|
TASIGNA 79062925 3635627 Live/Registered |
Novartis AG 2008-08-07 |
TASIGNA 78458843 2995313 Dead/Cancelled |
Novartis AG 2004-07-29 |